Overview

Pervasis has developed cell-based therapies that induce repair and regeneration in a wide array of tissues. The company’s lead products are based on our proprietary allogeneic endothelial cell technology, shown in preclinical studies to restore vascular function after injury and disruption.

Our flagship product, Vascugel®, is designed to treat vascular injury in a number of clinical settings, to include, yet not limited to vascular access, coronary bypass graft, limb salvage, and peripheral bypass failure.

Vascugel® has demonstrated significant progress in human clinical trials to date, and is currently well advanced in two Phase II trials in patients with End-Stage Renal Disease (ESRD). The “V-HEALTH” (Vascular intimal Hyperplasia: Extending Arterial and venous patency, Limiting vascular Trauma, and inhibiting Hyperplasia while re-establishing vascular health) Phase II Multi Arm clinical trials are evaluating Vascugel's safety and efficacy patients with ESRD that require a permanent arteriovenous fistulas (AVF) and arteriovenous grafts (AVG) access for hemodialysis.

The Phase I clinical trials, completed in November 2006, met all safety endpoints of the studies.

By working with world leading researchers and clinicians, Pervasis has generated a rich pipeline of product opportunities and has combined advances in polymers, drug delivery and cell-based therapy. Our products bring together proprietary knowledge from the laboratories of our acclaimed scientific founders, Robert Langer, Elazer Edelman, Joseph Vacanti and Helen Nugent. The company’s lead program was developed with assistance from the Deshpande Center at MIT.

With support from a leading syndicate of venture capital firms, Flagship Ventures, Polaris Venture Partners, and Highland Capital Partners, Pervasis is creating a revolution in the treatment of vascular disease.